CTCs combined with PTP4A1 expression can help better predict treatment efficacy in patients with esophageal cancer, which has important clinical value in blocking the disease progression and achieving individualized treatment of esophageal cancer metastasis. Here, PTP4A1 is linked to esophageal cancer.